PEV7 is a therapeutic vaccine based on a protein antigen, Sap2, a key virulence factor of vulvovaginal candidiasis, presented on the surface of virosomes.
The companies have also signed a long-term supply agreement under which CSL will supply Pevion with components for its virosomal vaccines.
Pevion Biotech said the PEV7 already obtained preliminary clinical results showing that the therapeutic vaccine is safe and immunogenic in healthy volunteers.
Pevion Biotech also said the ongoing PEV7 Phase I study is designed to demonstrate the safety and immunogenicity of the therapeutic vaccine candidate in healthy volunteers.